IZALONTAMAB SI-B001: A PROMISING EMERGING PROTEIN TREATMENT

This antibody SI-B001 is a significant development in hematologic care of difficult-to-treat multiple myeloma. The first-in-class antibody selectively targets BCMA within myeloma cells, leading to antibody-dependent cellular cytotoxicity while eliciting cancer-inhibiting patient's reactions. Init